KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Accumulated Depreciation & Amortization (2016 - 2025)

Pfizer (PFE) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $6.6 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 6.0% to $6.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 billion through Dec 2025, down 6.0% year-over-year, with the annual reading at $6.6 billion for FY2025, 6.0% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $6.6 billion at Pfizer, up from $1.7 billion in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $7.0 billion in Q4 2024, with the low at $1.5 billion in Q2 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.9 billion, with a median of $3.5 billion recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 30.32% in 2023, then crashed 68.17% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $5.2 billion in 2021, then fell by 2.45% to $5.1 billion in 2022, then grew by 24.21% to $6.3 billion in 2023, then increased by 11.49% to $7.0 billion in 2024, then dropped by 6.0% to $6.6 billion in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $6.6 billion, $1.7 billion, and $3.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.